ArticleFrontiers in public health2022
Time series models show comparable projection performance with joinpoint regression: A comparison using historical cancer data from World Health Organization.
Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluation and forecasting methods to estimate number of patients with non-Hodgkin lymphoma: a systematic literature review.Population health metrics · 2025Pooled it
- Spatiotemporal co-occurrence patterns and related risk factors of esophageal and lip and oral cavity cancers among older adults across 203 countries and territories: a machine learning-driven systematic analysis.Annals of medicine · 2026Article
- Trends and Burden of Human Rabies in Iran 2012-2021: A Cross-Sectional Study.Health science reports · 2026Article
- Long-term associations between animal-source food consumption and breast and prostate cancer incidence based on cointegration and ARIMAX models.Scientific reports · 2026Article
- National trends in bone-metastatic prostate cancer mortality in the United States, 1999-2024: a multiple-cause-of-death analysis with projections to 2040.Frontiers in oncology · 2026Article
- Article
- Suicides Mortality of Unemployed Individuals Becomes a Serious Public Health Concern in Japan in Post-COVID-19 Pandemic Era.International journal of environmental research and public health · 2025Article
- Comparing burden of ischemic stroke caused by high low-density lipoprotein cholesterol in global and China: trends and projections.Frontiers in neurology · 2025Article
- Unintentional fall mortality by place, sex, and age group among older Chinese adults, 2010-21.Journal of global health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer is one of the major causes of death and the projection of cancer incidences is essential for future healthcare resources planning. Joinpoint regression and average annual percentage change (AAPC) are common approaches for cancer projection, while time series models, traditional ways of trend analysis in statistics, were considered less popular. This study aims to compare these projection methods on seven types of cancers in 31 geographical jurisdictions. Methods: Using data from 66 cancer registries in the World Health Organization, projection models by joinpoint regression, AAPC, and autoregressive integrated moving average with exogenous variables (ARIMAX) were constructed based on 20 years of cancer incidences. The rest of the data upon 20-years of record were used to validate the primary outcomes, namely, 3, 5, and 10-year projections. Weighted averages of mean-square-errors and of percentage errors on predictions were used to quantify the accuracy of the projection results. Results: Among 66 jurisdictions and seven selected cancers, ARIMAX gave the best 5 and 10-year projections for most of the scenarios. When the ten-year projection was concerned, ARIMAX resulted in a mean-square-error (or percentage error) of 2.7% (or 7.2%), compared with 3.3% (or 15.2%) by joinpoint regression and 7.8% (or 15.0%) by AAPC. All the three methods were unable to give reasonable projections for prostate cancer incidence in the US. Conclusion: ARIMAX outperformed the joinpoint regression and AAPC approaches by showing promising accuracy and robustness in projecting cancer incidence rates. In the future, developments in projection models and better applications could promise to improve our ability to understand the trend of disease development, design the intervention strategies, and build proactive public health system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.